Two-year data support Bayer's Eylea with T&E dosing regimens in wet AMD
German pharma major Bayer (BAYN: DE) has announced two-year data which reconfirm the use of proactive Treat and Extend (T&E) dosing regimens with Eylea (aflibercept) solution for intravitreal injection for patients with wet age-related macular degeneration (wet AMD).
This includes data from the Phase IIIb/IV ARIES study,as well as results from an indirect comparison of published randomized clinical trials in wet AMD on either the anti-VEGF treatments aflibercept or ranibizumab.The study results were presented at the 19th Congress of the European Society of Retina Specialists (EURETINA) in Paris, France.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze